SPHRF - Remdesivir Gets The Starpharma DEP Treatment
DEP-coupled remdesivir (right) is soluble. Source Starpharma
I’m beginning to think that Starpharma (ASX:SPL) (SPHRY) (SPHRF) is showing signs of overnight success after 20 years of hard slog. The company’s core expertise is in dendrimer (nanoparticle) technology, with two core platforms. Firstly, it has a small positively charged dendrimer platform ((DEP)) which is used to enhance solubility and availability, especially of insoluble small molecule drugs. This reduces the toxicity and increases potency and half-life of the drugs. Here the application of the DEP platform to making remdesivir more available for earlier stage COVID-19